Asymchem(SZ:002821)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was ¥1,761,546,766.74, a decrease of 36.41% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥523,736,701.20, down 46.60% year-on-year[6]. - The total revenue for the first nine months of 2023 reached ¥6,383,057,146.18, reflecting an 18.29% decline year-on-year, but a 24.51% increase when excluding large orders[8]. - The small molecule CDMO business generated revenue of ¥5,565,000,000, a decrease of 22.01% year-on-year, but a 25.45% increase when excluding large orders[8]. - Emerging business revenue was ¥813,000,000, showing a year-on-year growth of 21.05%[8]. - Total operating revenue for Q3 2023 was CNY 6,383,057,146.18, a decrease of 18.3% compared to CNY 7,811,575,256.14 in the same period last year[22]. - Net profit for Q3 2023 was CNY 2,200,808,678.45, a decline of 19.1% compared to CNY 2,720,936,643.42 in Q3 2022[23]. Assets and Liabilities - The company's total assets increased to ¥19,764,226,099.24, an 8.36% rise from the end of the previous year[6]. - The company reported a total asset increase to CNY 19,764,226,099.24 as of September 30, 2023, up from CNY 18,239,273,651.93 at the beginning of the year[21]. - Current assets rose to CNY 13,059,172,427.71, an increase of 10.1% from CNY 11,860,458,372.35[20]. - The total liabilities decreased to CNY 2,292,382,441.40 from CNY 2,544,270,867.15, a reduction of 9.9%[21]. Earnings and Shareholder Information - Basic earnings per share for Q3 2023 were ¥1.45, down 43.84% compared to the same period last year[6]. - Basic and diluted earnings per share were both CNY 6.1, down from CNY 7.46 and CNY 7.43 respectively in the previous period[24]. - The total number of ordinary shareholders at the end of the reporting period was 50,563, with no preferred shareholders[15]. - The largest shareholder, ASYMCHEM LABORATORIES, holds 31.15% of the shares, totaling 115,133,168 shares[16]. Cash Flow and Investments - Cash flow from operating activities for the first nine months was ¥2,864,254,599.72, a slight increase of 0.90%[6]. - Cash received from operating activities rose by 303.43% to ¥172,736,270.48, primarily due to an increase in government subsidies related to capital[13]. - Cash inflow from investment activities totaled approximately CNY 20.10 billion, significantly higher than CNY 2.40 billion in the previous period[27]. - Cash outflow from investment activities was approximately CNY 21.00 billion, compared to CNY 5.08 billion in the previous period, resulting in a net cash flow from investment activities of approximately -CNY 895 million[27]. - The company received CNY 136.30 million in investment income, a recovery from a loss of CNY 4.38 million in the previous period[25]. Expenses and Costs - For the first nine months of 2023, the company's tax and additional charges increased by 59.61% to ¥59,382,485.19 compared to ¥37,204,484.78 in the same period of 2022, primarily due to additional taxes from export tax rebates[13]. - Sales expenses rose by 44.38% to ¥138,989,428.90, driven by continued market expansion and investments in the sales team and marketing activities[13]. - Cash outflow for purchasing goods and services decreased by 56.70% to ¥1,570,814,104.79, reflecting a reduction in large-scale raw material purchases compared to the previous year[13]. - Research and development expenses for Q3 2023 were CNY 513,114,161.26, an increase of 16.1% compared to CNY 442,204,004.98 in Q3 2022[22]. Other Financial Metrics - The weighted average return on equity was 3.18%, a decrease of 3.19% year-on-year[6]. - The total comprehensive income for the period was approximately CNY 2.21 billion, a decrease from CNY 2.75 billion in the previous period[24]. - The company’s capital reserve decreased to CNY 9,634,892,679.05 from CNY 10,143,534,669.29, a decline of 5.0%[21]. - The company’s deferred income tax assets increased to CNY 252,904,157.45 from CNY 177,857,982.20, a growth of 42.1%[20].